Ontuxizumab (50 mg/kg; i.v., 5 doses daily for 5 consecutive days) shows antitumor effects in human CD248 knock-in mice[1].
| Animal Model: | Human CD248 knock-in mice[1] |
| Dosage: | 50 mg/kg |
| Administration: | Intravenous injection via tail vein; 50 mg/kg, 5 doses daily for 5 consecutive days |
| Result: | Reduced tumor growth with a lower level of CD248 and α-SMA on neovasculature pericytes.
|
